Literature DB >> 12613204

Ceramide and sphingosine 1-phosphate in anti-cancer therapies.

David K Perry1, Richard N Kolesnick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12613204     DOI： 10.1007/0-306-48158-8_14

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


× No keyword cloud information.
  6 in total

1.  Discovery and evaluation of inhibitors of human ceramidase.

Authors:  Jeremiah M Draper; Zuping Xia; Ryan A Smith; Yan Zhuang; Wenxue Wang; Charles D Smith
Journal:  Mol Cancer Ther       Date:  2011-09-01       Impact factor: 6.261

2.  Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.

Authors:  Jagadish Kummetha Venkata; Ningfei An; Robert Stuart; Luciano J Costa; Houjian Cai; Woodrow Coker; Jin H Song; Kiwana Gibbs; Terri Matson; Elizabeth Garrett-Mayer; Zhuang Wan; Besim Ogretmen; Charles Smith; Yubin Kang
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

Review 3.  Targeting Sphingosine Kinases for the Treatment of Cancer.

Authors:  Clayton S Lewis; Christina Voelkel-Johnson; Charles D Smith
Journal:  Adv Cancer Res       Date:  2018-06-09       Impact factor: 6.242

4.  Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.

Authors:  Guido Bocci; Anna Fioravanti; Paola Orlandi; Teresa Di Desidero; Gianfranco Natale; Giovanni Fanelli; Paolo Viacava; Antonio Giuseppe Naccarato; Giulio Francia; Romano Danesi
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

5.  Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate.

Authors:  Fiorentina Roviezzo; Francesco Del Galdo; Gianfranco Abbate; Mariarosaria Bucci; Bruno D'Agostino; Edson Antunes; Gianfranco De Dominicis; Luca Parente; Francesco Rossi; Giuseppe Cirino; Raffaele De Palma
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-14       Impact factor: 11.205

6.  The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.

Authors:  Pasupathi Sundaramoorthy; Cristina Gasparetto; Yubin Kang
Journal:  Cancer Med       Date:  2018-05-15       Impact factor: 4.452
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.